Lactodifucotetraose, a human milk oligosaccharide, attenuates platelet function and inflammatory cytokine release

David S Newburg1, Ayse C Tanritanir2, Subrata Chakrabarti2

  • 1Higgins Hall - Biology, Boston College, 140 Commonwealth Avenue, Chestnut Hill, MA, 02467, USA. newburgd@bc.edu.

Insights

Human milk oligosaccharides, particularly lactodifucotetraose (LDFT), reduce inflammatory responses in infant platelets. This suggests LDFT may offer therapeutic benefits for inflammatory conditions in both infants and adults.

Area of Science:

  • Immunology
  • Neonatal Physiology
  • Biochemistry

Background:

  • Human milk possesses anti-inflammatory properties, benefiting breastfed infants who exhibit lower inflammatory disease rates.
  • Neonatal platelets are less responsive to agonists compared to adult platelets.
  • Breastfed infants absorb intact human milk oligosaccharides into circulation.

Purpose of the Study:

  • To investigate if human milk oligosaccharides can modulate infant platelet function.
  • To determine if oligosaccharides can reduce pro-inflammatory protein secretion from platelets.
  • To identify the specific active oligosaccharide component responsible for these effects.

Main Methods:

  • Platelets from human blood were isolated and exposed to thrombin, ADP, and collagen.
  • The effects of a natural human milk oligosaccharide mixture and individual purified oligosaccharides were tested.
  • Inhibition of platelet adhesion, aggregation, and inflammatory protein release (RANTES, sCD40L) was measured.

Main Results:

  • Human milk and its oligosaccharide mixture inhibited inflammatory protein release from platelets.
  • Lactodifucotetraose (LDFT) significantly inhibited thrombin-induced RANTES and sCD40L release.
  • LDFT also reduced platelet adhesion to collagen and aggregation induced by ADP or collagen.

Conclusions:

  • Lactodifucotetraose (LDFT) demonstrates potent anti-inflammatory effects on platelets.
  • LDFT may play a role in modulating hemostasis and suppressing inflammation in breastfed infants.
  • Further research into LDFT as a therapeutic agent for inflammatory conditions is warranted.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K